Jupiter Neurosciences Raises $2.0M in Offering; Extends Cash Runway

Jupiter Neurosciences, Inc. announced the closing of a registered direct offering, raising approximately $2.0 million through the sale of 7,142,858 shares of common stock. This capital infusion significantly reduces the company's debt, improving its balance sheet, and extends its cash runway. The funds will enable Jupiter to comfortably execute its Parkinson's Phase 2a trial and advance the transaction with PharmALA (ALA-002-MDMA), positioning the company for future financing opportunities.